Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Clinical trial NCT04895930 · UNKNOWN
Trial details
- NCT number
- NCT04895930
- Sponsor
- Shanghai Chest Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-12
- Primary completion
- 2023-11-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.